Evidence map›Paper›PMID 42063095›Full record

ArticleJournal of nanobiotechnology2026

AIEgen-mediated integration of plain DNA and hydrophobic compounds enabling three-in-one nanosystems for carrier-free delivery.

Yingqi Liang, Xianggui Yin, Yiming Ding, Zi'ang Yang, Shi Cao, Minjiang Chen, Lifei Zheng, Qing Liu, Jiansong Ji, Shiji Fang

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yingqi LiangSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Xianggui YinWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, China.
Yiming DingZhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, Key Laboratory of Precision Medicine of Lishui City, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Zi'ang YangSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Shi CaoWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, China.
Minjiang ChenZhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, Key Laboratory of Precision Medicine of Lishui City, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Lifei ZhengWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, China. zhenglf@ucas.ac.cn.
Qing LiuSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China. liuqing@ucas.ac.cn.
Jiansong JiZhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, Key Laboratory of Precision Medicine of Lishui City, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China. jijiansong@zju.edu.cn.
Shiji FangZhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, Key Laboratory of Precision Medicine of Lishui City, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China. fsj1216@163.com.

Funding

National Natural Science Foundation of China 22277018National Natural Science Foundation of China 22372049Wenzhou Institute, University of Chinese Academy of Sciences WIUCASQD2020015Wenzhou Institute, University of Chinese Academy of Sciences WIUCASQD2022006Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholar LR23B030001
6 · The paper itself

Abstract

DNA has been serving as a powerful and programmable vector for drug delivery, yet facile strategies for the direct loading of hydrophobic payloads onto DNA vehicles are still lacking but highly demanded. In this work, we report an AIEgen-mediated approach for the integration of plain DNA and hydrophobic molecules into nanospheres upon heating treatment. The broad applicability of this strategy is established by loading nine different hydrophobic molecules with high loading capacity, including six therapeutic drugs and three fluorescent dyes. Owing to the compact configuration, the nano-systems show superior stability under physiologically relevant conditions while the AIEgen displays significantly enhanced fluorescent signal and reactive oxygen species-generating ability upon light irradiation. In vitro studies validate the successful cellular delivery of the nanosystems, as evidenced by effective cell staining with fluorescent dyes and synergistic cytotoxicity from the combined action of loaded drugs and AIEgen-mediated photodynamic therapy (PDT). Finally, by using sorafenib and an antisense oligonucleotide (ASO), we demonstrate the synergistic antitumor efficacy of the nanodrug in vitro and in vivo: while ASO prolongs intracellular drug retention by down-regulating the efflux factor P-glycoprotein, sorafenib can amplify the PDT efficacy of the AIEgen by depleting glutathione and glutathione peroxidase 4. Therefore, our work establishes an effective AIEgen-mediated and heat-promoted strategy for creating multifunctional nanosystems, which may find widespread application in carrier-free delivery for disease theranostics.

Indexed as

DNADrug Delivery SystemsAnimalsAntineoplastic AgentsCell Line, TumorDrug CarriersFluorescent DyesHumansHydrophobic and Hydrophilic InteractionsMiceNanospheresPhotochemotherapyReactive Oxygen SpeciesSorafenibAntineoplastic AgentsDNADrug CarriersFluorescent DyesReactive Oxygen SpeciesSorafenibAggregation-induced emission luminogensCarrier-free deliveryDNAHydrophobic moleculesPhotodynamicSynergistic therapy

Identifiers

PMID42063095
PMCPMC13285454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.